Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
Launched by ABBVIE · Nov 8, 2017
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis
- • Patients voluntarily signed a patient authorization \& informed consent form.
- • Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
- • Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.
- Exclusion Criteria:
- • A patient who are contraindications to originator adalimumab (Humira®) as listed on the approved Korean label.
- • A patient who is participating on other interventional clinical trials
- • Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Busan, Busan Gwang Yeogsi, Korea, Republic Of
Cheonan, Chungcheongnamdo, Korea, Republic Of
Daegu, Daegu Gwang Yeogsi, Korea, Republic Of
Seongnam, Gyeonggido, Korea, Republic Of
Suwon Si, Gyeonggido, Korea, Republic Of
Bupyeong, , Korea, Republic Of
Iksan, Jeonrabugdo, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul City, Seoul, Korea, Republic Of
Busan, , Korea, Republic Of
Cheongju, , Korea, Republic Of
Gangnam Gu, , Korea, Republic Of
Goyang, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Bupyeong, Incheon Gwang Yeogsi, Korea, Republic Of
Patients applied
Trial Officials
AbbVie Inc.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials